MX2017005299A - Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. - Google Patents
Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.Info
- Publication number
- MX2017005299A MX2017005299A MX2017005299A MX2017005299A MX2017005299A MX 2017005299 A MX2017005299 A MX 2017005299A MX 2017005299 A MX2017005299 A MX 2017005299A MX 2017005299 A MX2017005299 A MX 2017005299A MX 2017005299 A MX2017005299 A MX 2017005299A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pgi2
- receiver
- solvate
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Abstract
Se proporcionan en algunas modalidades paquetes de ajuste de la dosis, kits, y métodos de tratamiento de hipertensión arterial pulmonar que comprende recetar y/o administrar a un paciente que necesita del mismo ácido 2-(((1r,4r)-4-(((4-clorofenil)(fenil)carb amoiloxi)metil) ciclohexil)metoxi)acético (Compuesto 1), o una sal, hidrato, o solvato farmacéuticamente aceptable del mismo, por medio de un esquema de ajuste de la dosis que comprende el ajuste ascendente de la dosis del Compuesto 1, o una sal, hidrato, o solvato farmacéuticamente aceptable del mismo, durante un periodo de no más de alrededor de nueve semanas hasta que se administre una dosis optimizada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067916P | 2014-10-23 | 2014-10-23 | |
| PCT/US2015/056824 WO2016065103A1 (en) | 2014-10-23 | 2015-10-22 | Method of treating conditions related to the pgi2 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005299A true MX2017005299A (es) | 2017-07-28 |
| MX389330B MX389330B (es) | 2025-03-20 |
Family
ID=54365450
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009909A MX394186B (es) | 2014-10-23 | 2015-10-22 | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2 |
| MX2017005299A MX389330B (es) | 2014-10-23 | 2015-10-22 | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. |
| MX2022009032A MX2022009032A (es) | 2014-10-23 | 2017-04-21 | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009909A MX394186B (es) | 2014-10-23 | 2015-10-22 | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009032A MX2022009032A (es) | 2014-10-23 | 2017-04-21 | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US10537546B2 (es) |
| EP (2) | EP3209291B1 (es) |
| JP (2) | JP6768646B2 (es) |
| KR (2) | KR102484589B1 (es) |
| CN (2) | CN107106532A (es) |
| AU (1) | AU2015335841B2 (es) |
| CA (1) | CA2999467C (es) |
| EA (1) | EA201790905A1 (es) |
| ES (1) | ES2969469T3 (es) |
| MX (3) | MX394186B (es) |
| NZ (1) | NZ731751A (es) |
| UA (1) | UA122778C2 (es) |
| WO (1) | WO2016065103A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3209291B1 (en) | 2014-10-23 | 2023-12-06 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the pgi2 receptor |
| KR102916884B1 (ko) * | 2016-11-10 | 2026-01-22 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
| EP3977985B1 (en) * | 2017-03-01 | 2023-09-06 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| WO2018202471A1 (en) * | 2017-05-02 | 2018-11-08 | Bayer Aktiengesellschaft | Tmem16a modulation for diagnostic or therapeutic use in pulmonary hypertension (ph) |
| WO2019222764A1 (en) * | 2018-05-16 | 2019-11-21 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| US20210154193A1 (en) * | 2019-11-25 | 2021-05-27 | PHPrecisionMed, LLC | Pharmaceutical compositions for the treatment of pulmonary hypertension |
| EP4479374A1 (en) | 2022-02-15 | 2024-12-25 | United Therapeutics Corporation | Crystalline prostacyclin (ip) receptor agonist and uses thereof |
| WO2025193579A1 (en) | 2024-03-11 | 2025-09-18 | United Therapeutics Corporation | Methods of making ip-receptor agonists |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2945530A1 (de) | 1979-11-10 | 1981-06-04 | Chemische Werke Hüls AG, 4370 Marl | Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide |
| JPH03160438A (ja) | 1989-11-20 | 1991-07-10 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| EP0442448A3 (en) | 1990-02-13 | 1992-08-12 | Bristol-Myers Squibb Company | Heterocyclic carboxylic acids and esters |
| CA2085844A1 (en) | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
| JPH06329598A (ja) | 1993-05-19 | 1994-11-29 | Daicel Chem Ind Ltd | エステルの製造方法 |
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| JPH11269138A (ja) | 1998-03-20 | 1999-10-05 | Mitsubishi Paper Mills Ltd | 有機塩基発生剤 |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| WO2002055484A1 (en) | 2001-01-12 | 2002-07-18 | Takeda Chemical Industries, Ltd. | Biaryl compound, process for producing the same, and agent |
| AU2002322585A1 (en) | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| HUP0401963A3 (en) | 2001-08-09 | 2006-01-30 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| US7086532B2 (en) * | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
| TWI293715B (en) | 2002-10-10 | 2008-02-21 | Sipix Imaging Inc | A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| JP4402413B2 (ja) | 2003-09-29 | 2010-01-20 | 財団法人２１あおもり産業総合支援センター | Ｕ字型化合物およびこれを含む液晶組成物 |
| DE102004006785A1 (de) | 2004-02-11 | 2005-09-08 | Mayr, Herbert, Prof. Dr. | Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure |
| WO2006023844A2 (en) | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
| JP4792731B2 (ja) | 2004-11-12 | 2011-10-12 | Ｄｉｃ株式会社 | 重合性液晶組成物及び当該組成物の硬化物 |
| WO2007051255A1 (en) | 2005-11-04 | 2007-05-10 | The University Of Sydney | Process for the preparation of compounds containing an azacyclic ring system |
| JP2007161867A (ja) | 2005-12-14 | 2007-06-28 | Toyo Ink Mfg Co Ltd | インキ組成物 |
| JP2009536659A (ja) | 2006-05-09 | 2009-10-15 | ヘマクエスト・ファーマシューティカルズ，インコーポレーテッド | 血液疾患の治療法 |
| BRPI0816690A2 (pt) | 2007-09-12 | 2016-11-01 | Merz Pharma Gmbh & Co Kgaa | derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição |
| CN103483226A (zh) * | 2008-03-18 | 2014-01-01 | 艾尼纳制药公司 | 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂 |
| JP5603343B2 (ja) | 2008-11-26 | 2014-10-08 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連する障害を処置するために有用なプロスタサイクリン（ｐｇｉ２）受容体モジュレーターとしてのピラゾリル置換炭酸誘導体 |
| ES2548882T3 (es) | 2008-12-08 | 2015-10-21 | Arena Pharmaceuticals, Inc. | Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos |
| WO2011037613A1 (en) | 2009-09-23 | 2011-03-31 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| JP3160438U (ja) | 2010-04-14 | 2010-06-24 | 孝枝 袴田 | 弦楽器演奏練習補助具 |
| EP3209291B1 (en) | 2014-10-23 | 2023-12-06 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the pgi2 receptor |
| EP3977985B1 (en) * | 2017-03-01 | 2023-09-06 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
-
2015
- 2015-10-22 EP EP15787849.7A patent/EP3209291B1/en active Active
- 2015-10-22 EA EA201790905A patent/EA201790905A1/ru unknown
- 2015-10-22 AU AU2015335841A patent/AU2015335841B2/en active Active
- 2015-10-22 KR KR1020227030479A patent/KR102484589B1/ko active Active
- 2015-10-22 MX MX2021009909A patent/MX394186B/es unknown
- 2015-10-22 EP EP23211525.3A patent/EP4349330A3/en active Pending
- 2015-10-22 JP JP2017522006A patent/JP6768646B2/ja active Active
- 2015-10-22 WO PCT/US2015/056824 patent/WO2016065103A1/en not_active Ceased
- 2015-10-22 CA CA2999467A patent/CA2999467C/en active Active
- 2015-10-22 CN CN201580069031.5A patent/CN107106532A/zh active Pending
- 2015-10-22 US US15/520,864 patent/US10537546B2/en active Active
- 2015-10-22 UA UAA201704985A patent/UA122778C2/uk unknown
- 2015-10-22 KR KR1020177013394A patent/KR102441249B1/ko active Active
- 2015-10-22 ES ES15787849T patent/ES2969469T3/es active Active
- 2015-10-22 CN CN202111087825.8A patent/CN114452279A/zh active Pending
- 2015-10-22 NZ NZ731751A patent/NZ731751A/en unknown
- 2015-10-22 MX MX2017005299A patent/MX389330B/es unknown
-
2017
- 2017-04-21 MX MX2022009032A patent/MX2022009032A/es unknown
-
2019
- 2019-12-06 US US16/706,424 patent/US10688076B2/en active Active
-
2020
- 2020-05-01 JP JP2020081099A patent/JP2020114882A/ja not_active Withdrawn
- 2020-05-08 US US16/870,777 patent/US11000500B2/en active Active
-
2021
- 2021-04-12 US US17/227,740 patent/US11426377B2/en active Active
-
2022
- 2022-07-12 US US17/863,098 patent/US11826337B2/en active Active
-
2023
- 2023-01-30 US US18/161,758 patent/US20230172898A1/en not_active Abandoned
- 2023-10-20 US US18/491,524 patent/US12239627B2/en active Active
-
2025
- 2025-01-16 US US19/024,658 patent/US20250152549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017005299A (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| BR112015002285A2 (pt) | métodos de tratamento de câncer utilizando 3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| MX2018005729A (es) | Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana. | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| JP2016510326A5 (es) | ||
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| MX2020013157A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| ES2663836T3 (es) | Carboxamidas de quinolina para su uso en el tratamiento de leucemia | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| NZ708802A (en) | Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound | |
| AR114930A1 (es) | Composición farmacéutica | |
| MX380172B (es) | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| MX2022003982A (es) | Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. | |
| MX2014003867A (es) | Tratamiento de rinitis. | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically |